Highway Pharmaceuticals

Highway Pharmaceuticals

Safer, better pharmaceuticals for animal autoimmune diseases

Print
Claim My Business
Form C
View on Wefunder
Security Type
CAFES
Categories
Technology, Financial Services, Healthcare & Medical, Pets/Animals, Education
Min Investment
$100
Location
Boston, MA
Expected Close Date
April 30, 2023
Target Raise
$50.00K-$124.00K
No. Investors
49
Security Price
$1
Website
highwaypharm.com
Number of Employees
1
Cash
$0
Revenue
$0
Short Term Debt
$0
Cost of Goods
$0
Long Term Debt
$0
Net Income
$-23,337

Key Deal Facts

A drug for a $1 billion/year disease in cats
Proven mechanism of action and experienced team
Licensing interest from major pharmaceutical companies
A chance to help a lot of very sick cats

Management Team / Advisory Board Bios

Trevor Klee PresidentMultiple patents granted for invention of technology., Ken Kashkin COOCOO of Chromocell, a ~100 person biotech company with >$30 million in revenue. Responsible for collaboration with Astellas Pharma worth >$515M in upfront and milestone, and advancing associated compound from target through phase II trials,
Amount Raised : $102,455
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment